Trial Profile
A Prospective Observational, Long Term Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Imlifidase (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Hansa Biopharma AB
- 17 Oct 2023 According to a Hansa Biopharma AB media release, the company is continuing to analyze the data from 17-HMedIdeS-14 along with the extended pooled analysis and plans to share further data in 2024.
- 17 Oct 2023 Results from an extended pooled analysis using data from the 17-HMedIdeS-14 study, long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, showing sustained positive outcomes out to 5 years in the majority of highly sensitized patients, were presented in a Hansa Biopharma AB Media Release
- 23 Feb 2023 Status changed from active, no longer recruiting to completed.